NCT00674609 2023-05-03
SPRAY
Jazz Pharmaceuticals
Phase 3 Completed
Clinical Trials
8 trialsNCT00675948 2023-05-03
Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01337089 2023-04-12
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01361607 2023-04-12
SPRAY III
Jazz Pharmaceuticals
Phase 3 Completed
NCT01424566 2023-04-12
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 3 Completed
NCT01812603 2022-12-20
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT01812616 2022-12-20
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT02073474 2022-12-20
An Observational Post-Marketing Safety Registry of Sativex®
Jazz Pharmaceuticals
Completed